EUVIMEDEUVIMED entdecken
Crossref

Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients

Jochen G Mainz, Vivien Greiner, Pauline Sadrieh, Louise Polte, Ingo Baumann, Franziska Duckstein, Anton Barucha, Suzanne van Dullemen, Olaf Eickmeier iD, Carlos Zagoya iD

Pediatric Pulmonology · 2026

DOI: 10.1002/ppul.71507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2026. Verfasst von Jochen G Mainz und 9 weiteren Autor:innen. Beteiligte Einrichtung: CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Brandenburg an der Havel, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Aminophenols, Quinolones. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For people with cystic fibrosis (pwCF) carrying susceptible mutations, elexacaftor/tezacaftor/ivacaftor (ETI) has changed the course of their lives. Organ manifestations critically affecting both respiratory and digestive tracts have been found to improve considerably. Consequently, ETI‐associated reductions in sinonasal symptoms (SNS) deriving from the upper respiratory tract are consistently reported. However, although substantial ETI‐related declines in the burden of abdominal symptoms (AS) have been reported using the CFAbd‐Score, their correlation with SNS changes has not been studied.

Aims

Assessing correlations between ETI‐related changes in pwCF SNS and AS.

Methods

The German adapted version of the Sinonasal‐Outcome‐Test 20 (SNOT‐20‐GAV) and the CFAbd‐Score, the first CF‐specific gastrointestinal (GI) patient‐reported outcome measure developed and validated following FDA guidelines, were simultaneously administered. PwCF completing both paired questionnaires, at least once before and after ETI initiation, were included.

Results

In two German CF‐centers, n = 31 pwCF (18 f, mean‐age 13 years) were included, completing n = 106 paired questionnaires. During ETI therapy, significant decreases ( p < 0.05) were observed for the mean total CFAbd‐Score (10.9→5.8pts[−47%]) as well as all sub‐scores (‘pain’: −61%, ‘disorders of bowel movement’: −56%, ‘GERD’: −54%, ‘disorders of appetite’: −50% and ‘QoL‐impairment’:−67%). Analogously, SNS significantly improved (total SNOT: 10.1→3.4pts[−66%] and its 3 domains: primary and secondary nasal symptoms, and SNS‐related QoL [−68%/−81%/−54%]). However, the correlation between changes in symptoms related to upper‐respiratory and GI tracts was only modest.

Conclusion

The burden of symptoms captured with the CFAbd‐Score and the SNOT‐20‐GAV significantly and markedly decreased after ETI initiation. The modest association between changes in both organ‐specific symptom scores supports the previously reported individualized electrophysiological responses observed in nasal‐potential and intestinal‐current measurements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisIndolesAminophenolsQuinolonesBenzodioxolesPyridinesGastrointestinal DiseasesPyrrolidinesChloride Channel AgonistsPyrazolesHumansFemaleMaleAdolescentChildDrug CombinationsPatient Reported Outcome MeasuresYoung AdultGermanyAdultTreatment OutcomeSurveys and QuestionnairesQuinolines

Stichwörter der Autor:innen

CFTR‐modulatorGIabdominalcystic fibrosispatient reported outcome measure PROMrhinologicsymptoms

Substanzen

IndolesAminophenolsQuinolonesDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationBenzodioxolesPyridinesPyrrolidinesChloride Channel AgonistsPyrazoles

Autor:innen und Institutionen

  • CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Brandenburg an der Havel, Germany.
  • Medizinische Hochschule Brandenburg (MHB), Universitätsklinikum, Brandenburg an der Havel, Germany.
  • Department of Otorhinolaryngology, University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Gastroenterology, Brandenburg Medical School (Theodor Fontane), Brandenburg an der Havel, Germany.
  • Department of Pediatrics, Division of Pneumology, Allergology, Infectious Diseases, Gastroenterology, Goethe University, Frankfurt a.M., Germany.

ORCID-Profile: Olaf Eickmeier, Carlos Zagoya

Zitieren

APA

Mainz, J. G., Greiner, V., Sadrieh, P., Polte, L., Baumann, I., Duckstein, F., Barucha, A., van Dullemen, S., Eickmeier, O., & Zagoya, C. (2026). Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71507

Vancouver

Mainz JG, Greiner V, Sadrieh P, Polte L, Baumann I, Duckstein F, et al. Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients. Pediatric Pulmonology. 2026. doi:10.1002/ppul.71507

BibTeX
@article{Mainz2026,
  author = {Mainz, Jochen G and Greiner, Vivien and Sadrieh, Pauline and Polte, Louise and Baumann, Ingo and Duckstein, Franziska and Barucha, Anton and van Dullemen, Suzanne and Eickmeier, Olaf and Zagoya, Carlos},
  title = {Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients},
  journal = {Pediatric Pulmonology},
  year = {2026},
  doi = {10.1002/ppul.71507}
}
Kostenlos starten →